全國(guó)服務(wù)咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡(jiǎn)要描述：Dorzolamide hydrochloride 130693-82-2Dorzolamide Hydrochloride is the hydrochloride salt form of dorzolamide, an inhibitor of carbonic anhydrase
產(chǎn)品型號(hào)：abs47027912廠商性質(zhì)：生產(chǎn)廠家更新時(shí)間：2026-01-07訪 問(wèn) 量：560產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 130693-82-2 |
|---|---|---|---|
| 分子式 | C10H17ClN2O4S3 | 純度 | 99% |
| 分子量 | 360.9 | 貨號(hào) | abs47027912 |
| 規(guī)格 | 5mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is the hydrochloride salt form of dorzol | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Dorzolamide hydrochloride 130693-82-2
| 產(chǎn)品描述 | |
| 描述 | Dorzolamide Hydrochloride is the hydrochloride salt form of dorzolamide, an inhibitor of carbonic anhydrase, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions. Distributed throughout many cells and tissues, various carbonic anhydrases play important roles in mineral and metabolic homeostasis. |
| 純度 | 99% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 鹽酸多佐胺；L671152 hydrochloride；MK507 hydrochloride |
| 外觀 | 白色粉末 |
| 可溶性/溶解性 | Water : 12 mg/mL (33.3 mM) |
| 生物活性 | |
| 靶點(diǎn) | Carbonic anhydrase II,Carbonic anhydrase IV,Carbonic anhydrase I |
| In vitro(體外研究) | Dorzolamide is a powerful inhibitor of carbonic anhydrase (CA) II that penetrates the sclera and cornea to reach the ciliary process and lowers formation of HCO3 and aqueous humor. Dorzolamide causes a vasodilatation of retinal arteries, pre-contracted by three different mechanisms by direct action and presumably independent of changes in extracellular pH. |
| In vivo(體內(nèi)研究) | Dorzolamide, administered twice and three times daily, significantly decreases intraocular pressure (IOP) in glaucomatous dogs on the first day (twice daily 7.6 mmHg, and three times daily 16.4 mmHg) that is even greater by day 5 (twice daily 10.4 mmHg, and three times daily 13.9 mmHg). Dorzolamide (instilled in the drug eye for day 1 through to day 5) combined with oral methazolamide (administered from day 3 through to day 5) significantly lowers IOP in the eye on day 1, for day 3 and for all of day 5 for both eyes. Dorzolamide (2%) instilled three times daily produces similar IOP declines compared to the combination of oral methazolamide and 2% dorzolamide administered twice daily. Dorzolamide hydrochloride induces a very large IOP reduction and is found to be also well effective at night in rabbit. Dorzolamide maximally lowers the intraocular pressure (IOP) of glaucomatous monkeys by 22%, 30% and 37%, respectively. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號(hào)申江科創(chuàng)園18棟
郵箱：
傳真：